Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Naunyn-Schmiedeberg's Archives of Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s002109900152PMID 10651152
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Review of its Pharmacology and Therapeutic Potential in the Management of Nausea and Vomiting Induced by Chemotherapy, Radiotherapy or Surgery

  2012cited by this paper
• Neuropharmacology of 5-HT3 Receptor Ligands

  2000cited by this paper
• The 5-HT3B subunit is a major determinant of serotonin-receptor function

  1999cited by this paper
• Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

  1998cited by this paper
• Autoreceptors can modulate 5-hydroxytryptamine release from porcine and human small intestine in vitro

  1998cited by this paper
• Molecular cloning of alternatively spliced human 5-HT3 receptor cDNAs.

  1998cited by this paper
• Anticancer therapy-induced emesis: existence of an intestinal subtype of the 5-HT3 receptor?

  1998cited by this paper
• Antiemetic activity of ondansetron in acute gastroenteritis

  1997cited by this paper
• Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of σ2 binding sites

  1996cited by this paper
• Characterization of a human 5‐hydroxytryptamine3 receptor type A (h5‐HT3R‐AS) subunit stably expressed in HEK 293 cells

  1996cited by this paper
• New oral agents for type II diabetes. Taking a more aggressive approach to therapy.

  1995cited by this paper
• Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

  1995cited by this paper
• Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies.

  1995cited by this paper
• Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy.

  1995cited by this paper
• New oral agents for type II diabetes.

  1995cited by this paper
• Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis.

  1995cited by this paper
• Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species.

  1995cited by this paper
• An electrophysiological investigation of the properties of a murine recombinant 5‐HT3 receptor stably expressed in HEK 293 cells

  1995cited by this paper
• Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.

  1995cited by this paper
• Comparative Tolerability Profiles of Oral Antidiabetic Agents

  1994cited by this paper
• Pharmacological characterization of the apparent splice variants of the murine 5-HT3 R-A subunit expressed in Xenopus laevis oocytes

  1994cited by this paper
• Treatment of chronic cryptosporidiosis-induced diarrhea with a serotonin receptor antagonist.

  1994cited by this paper
• Cloning and functional expression of an apparent splice variant of the murine 5-HT3 receptor A subunit.

  1993cited by this paper
• Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine

  1993cited by this paper
• Characterization of 5‐HT3 receptors of N1E‐115 neuroblastoma cells by use of the influx of the organic cation [14C]‐guanidinium

  1993cited by this paper
• Mechanisms of vomiting induced by serotonin-3 receptor agonists in the cat: effect of vagotomy, splanchnicectomy or area postrema lesion.

  1992cited by this paper
• Biguanides and NIDDM

  1992cited by this paper
• Changes inserotonin metabolism incancerpatients: itsrelationship to nauseaandvomiting induced bychemotherapeutic drugs

  1992cited by this paper
• Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs.

  1992cited by this paper
• Cisplatin increases the release of 5-hydroxytryptamine (5-HT) from the isolated vascularly perfused small intestine of the guinea-pig: Involvement of 5-HT3 receptors

  1991cited by this paper
• The agonist properties of m‐chlorophenylbiguanide and 2‐methyl‐5‐hydroxytryptamine on 5‐HT3 receptors in N1E‐115 neuroblastoma cells

  1991cited by this paper
• Regulation of serotonin release from the intestinal mucosa.

  1991cited by this paper
• 1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT3 receptor agonist.

  1990cited by this paper
• Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.

  1990cited by this paper
• The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret.

  1988cited by this paper
• Spontaneous release of endogenous 5-hydroxytryptamine and 5-hydroxyindoleacetic acid from the isolated vascularly perfused ileum of the guinea-pig.

  1987cited by this paper
• Diarrhea and Metformin in a Diabetic Clinic

  1983cited by this paper
• Relative activities of substances related to 5-hydroxytryptamine as depolarizing agents of superior cervical ganglion cells.

  1981cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Synthalin, Buformin, Phenformin, and Metformin: A Century of Intestinal “Glucose Excretion” as Oral Antidiabetic Strategy in Overweight/Obese Patients

  2025cites this paper
• Metformin reduces inflammatory nociception in mice through a serotonin-dependent mechanism.

  2025cites this paper
• Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems

  2025cites this paper
• Therapeutic Potential of Baicalein in Endometrial Cancer: Suppression of mTOR Signaling and Synergy with Metformin

  2025cites this paper
• View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

  2024cites this paper
• Baicalein, a dietary flavonoid, enhances the insulin‐sensitizing effect of metformin to prevent type 2 diabetes via the regulation of lipid metabolism and gut microenvironment

  2024cites this paper
• Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials

  2024cites this paper
• Acupuncture and Drug Combination Therapy for Abnormal Glucose Metabolism: Exploring Synergistic Enhancement and Reduced Toxicity Mechanisms

  2024cites this paper
• Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with meta-regression of observational studies

  2024cites this paper
• A Convenient Synthesis of Short α-/β-Mixed Peptides as Potential α-Amylase Inhibitors

  2024cites this paper
• Metformin-Associated Gastrointestinal Adverse Events Are Reduced by Probiotics: A Meta-Analysis

  2024cites this paper
• Improvement of Theaflavins on Glucose and Lipid Metabolism in Diabetes Mellitus

  2024cites this paper
• Metformin intolerance in type 2 diabetes mellitus – the possibility of using a multi-strain probiotic

  2024influential citation
• Emerging Perspectives on the Impact of Diabetes Mellitus and Anti-Diabetic Drugs on Premenstrual Syndrome. A Narrative Review

  2024cites this paper
• Microbiome differences related to metformin intolerance among Black individuals with diabetes, a pilot cross-sectional study

  2023cites this paper
• Effects of Medications on Heat Loss Capacity in Chronic Disease Patients: Health Implications Amidst Global Warming

  2023cites this paper
• Metformin: A Promising Alternative to Alleviate the Gastrointestinal Side Effects Associated

  2023cites this paper
• Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders

  2022cites this paper
• Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials

  2022cites this paper
• A Review on Metformin: Clinical Significance and Side Effects

  2021cites this paper
• Metformin turns 62 in Pharmacotherapy: emergence of non-glycaemic effects and potential novel Therapeutic applications.

  2021cites this paper
• Metformin acts on the gut-brain axis to ameliorate antipsychotic-induced metabolic dysfunction.

  2021cites this paper
• Type 2 Diabetes Mellitus

  2021cites this paper
• Metformin: Up to Date.

  2020cites this paper
• Mouse model of metformin-induced diarrhea

  2020cites this paper
• Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood

  2020cites this paper
• Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice.

  2019cites this paper
• Metformin: Mechanisms in Human Obesity and Weight Loss

  2019cites this paper
• Effect of Metformin on Antipsychotic-Induced Metabolic Dysfunction: The Potential Role of Gut-Brain Axis

  2019cites this paper
• Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease.

  2019cites this paper
• Mechanism of action of metformin on glucose 6-phosphate in hepatocytes

  2019cites this paper
• Effects of Drugs and Excipients on Hydration Status

  2019cites this paper
• Metformin and its gastrointestinal problems: A review

  2018cites this paper
• Pharmacokinetics of metformin in patients with gastrointestinal intolerance

  2018cites this paper
• Tropisetron modulates peripheral and central serotonin/insulin levels via insulin and nuclear factor kappa B/receptor for advanced glycation end products signalling to regulate type-2 diabetes in rats

  2018cites this paper
• The mechanisms of action of metformin

  2017cites this paper
• University of Dundee The mechanisms of action of metformin

  2017cites this paper
• A story of metformin‐butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?

  2017cites this paper
• Metabolic study of Alzheimer’s disease using mutant C. elegans

  2017cites this paper
• University of Dundee Effect of Serotonin Transporter 5HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin Dujic,

  2016cites this paper
• Evaluation Series on Safety and Efficacy of Nutritional Supplements in Newly Diagnosed Hyperglycemia: A Placebo-Controlled, Randomized Study

  2016cites this paper
• Metformin and the gastrointestinal tract

  2016cites this paper
• Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study

  2016influential citation
• Metformin: From Research to Clinical Practice.

  2016cites this paper
• [Metformin - new data for an "old", but efficient, safe and reliable antidiabetic drug].

  2016cites this paper
• Metformin Attenuates Aβ Pathology Mediated Through Levamisole Sensitive Nicotinic Acetylcholine Receptors in a C. elegans Model of Alzheimer’s Disease

  2016cites this paper
• Diabetes and oral therapies: A review of oral therapies for diabetes mellitus

  2016cites this paper
• Effects of Caralluma fimbriata extract on cardiovascular and metabolic disorders

  2016cites this paper
• Metformin – újabb adatok egy megbízható és hatékony „régi” vércukorcsökkentő készítményről

  2016cites this paper
• Prediction and validation of enzyme and transporter off-targets for metformin

  2015cites this paper
• Metformin—mode of action and clinical implications for diabetes and cancer

  2014cites this paper
• Title: Association of Organic Cation Transporter 1 with Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study Short title: Metformin intolerance and OCT1 transport

  2014cites this paper
• Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study

  2014cites this paper
• Investigating the effect of emetic and aversive compounds on Dictyostelium identifies a novel non-sentient model for bitter tastant research

  2013cites this paper
• Interplay between metformin and serotonin transport in the gastrointestinal tract: A novel mechanism for the intestinal absorption and adverse effects of metformin

  2013cites this paper
• Effects of pregnane glycosides on food intake depend on stimulation of the melanocortin pathway and BDNF in an animal model.

  2013cites this paper
• Distribution of Serotonin-immunoreactive Enterochromaffin Cells in the Gastrointestinal Tract of the Least Shrew (Cryptotis parva)

  2012cites this paper
• Brainstem sensing of meal-related signals in energy homeostasis.

  2012cites this paper
• Investigating the Effect of Emetic Compounds on Chemotaxis in Dictyostelium Identifies a Non-Sentient Model for Bitter and Hot Tastant Research

  2011cites this paper
• Metformin and digestive disorders.

  2011cites this paper
• Antidepressant Medicine Use and Risk of Developing Diabetes During the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

  2010cites this paper
• Metformin: a review.

  2008cites this paper
• Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas.

  2007cites this paper
• Case studies in swelling polymeric gastric retentive tablets

  2006cites this paper
• The Contribution of cocoa additive to cigarette smoking addiction

  2003cites this paper
• Ondansetron and Metformin-Induced Gastrointestinal Side Effects

  2003influential citation
• Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes:

  2001cites this paper